Search the Newsreel

Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $30.31 Million Stake in Pfizer Inc. $PFE

The Commonwealth of Pennsylvania Public School Employees’ Retirement System recently reduced its stake in Pfizer Inc. by 5% in the second quarter, selling 65,593 shares but still holding 1.26 million shares valued at approximately $30.31 million. Despite this reduction, institutional investors collectively own a …

Hennessy Advisors Inc. Acquires 63,013 Shares of Pfizer Inc. $PFE

Hennessy Advisors Inc. increased its stake in Pfizer Inc. by 27% in the second quarter, acquiring 63,013 additional shares and bringing its total holdings to 296,113 shares valued at approximately $7.13 million. Despite institutional investors owning 68.36% of Pfizer, analyst sentiment remains cautious with …

Property For Industry Limited Revenue Breakdown – NZX:PFI

Notable trades: Netflix, Coca-Cola, Pfizer among notable names

Insider transactions were seen across major firms this week, including Netflix (NFLX [https://seekingalpha.com/symbol/NFLX]), Merck (MRK [https://seekingalpha.com/symbol/MRK]), and Pfizer (PFE [https://seekingalpha.com/symbol/PFE]). The following trades took place between August 10 and August 14. * Netflix (NFLX [https://seekingalpha.com/symbol/NFLX]) Chief Financial Officer Spencer Neumann sold 9,248 shares at …

OppFi (OPFI) CEO Todd Schwartz purchases 20,000 shares via trust at $7.20

OppFi Inc. CEO Todd G. Schwartz purchased 20,000 shares of Class A Common Stock on August 14, 2026, at a weighted average price of $7.2006 per share. The shares were acquired indirectly through the TGS Revocable Trust, of which Schwartz is the sole trustee, …

Pfizer Inc. $PFE Stock Position Lifted by Park National Corp OH

Park National Corp OH significantly increased its stake in Pfizer Inc. by 332.1% in the second quarter, now holding 242,081 shares valued at approximately $5.8 million. Despite this, analysts maintain a "Hold" rating for Pfizer with a $28.28 price target, citing concerns over post-COVID …

Independent Financial Group LLC Purchases 57,994 Shares of Pfizer Inc. $PFE

Independent Financial Group LLC significantly increased its stake in Pfizer Inc. during the second quarter, buying 57,994 additional shares and bringing its total holding to 122,166 shares valued at $2.94 million. Institutional investors collectively own 68.36% of Pfizer, which recently reported strong quarterly earnings …

What Pfizer (PFE)'s EMA Lyme Vaccine Filing and Updated Outlook Means For Shareholders

Pfizer recently reported Q2 2026 results, showing a net loss but raising its full-year revenue guidance to US$60.5 billion–US$62.5 billion. Concurrently, the European Medicines Agency validated the Marketing Authorization Application for Pfizer and Valneva’s Lyme disease vaccine candidate, a step that could diversify Pfizer's …

Pfizer (PFE) Stock Looks Reasonable On Returns But Stretched On Earnings

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Pfizer stock has delivered a roughly 28% decline over the past five years, yet recent gains and a mixed set of valuation checks …

New owner secures mystery tenant for Everett plant shelved by Pfizer

A California developer has purchased the unfinished $350 million biomanufacturing facility in Everett that Pfizer halted after acquiring Seagen in 2023. The new owner has also secured a tenant for the plant, though the tenant's identity remains undisclosed. This development provides a future for …

Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase

Three Pfizer insiders executed transactions directly on the heels of the drugmaker’s second-quarter earnings report. Continue Reading

Pfizer’s Korean Paxlovid Study Signals Ongoing Value in High‑Risk COVID Market

Pfizer Inc. has completed a real-world study in Korea on Paxlovid, demonstrating its effectiveness in older adults within long-term care hospitals against severe COVID-19, mortality, and decline in daily function. This observational study, which compared Paxlovid users to non-users matched on various factors, supports …

Pfizer (PFE) reports $170.4M across 20 institutional holdings in 13F

Pfizer Inc. (PFE), acting as an institutional investment manager, filed a quarterly Form 13F holdings report. The report details 20 equity investment positions with a total value of $170.4 million. The filing was signed by Madelyn D. Purcell, Assistant General Counsel, and indicates that …

LMR entities (OPFI) report expiry of warrants tied to 2.5% OppFi stake

LMR investment entities and their principals, Ben Levine and Stefan Renold, have filed an updated ownership report for OppFi Inc. (OPFI), indicating the expiry of warrants that previously represented a 2.5% stake in the company. These warrants, covering 2,330,473 shares of Class A common …

QRG Capital Management Inc. Acquires 49,804 Shares of Pfizer Inc. $PFE

QRG Capital Management Inc. increased its stake in Pfizer Inc. by 5.8% during the second quarter, acquiring 49,804 additional shares and bringing its total holdings to 902,308 shares valued at approximately $21.7 million. This comes as institutional investors collectively own 68.36% of Pfizer's stock. …

Pfizer Inc.: Konsensus der Analysten und Kursziel | 852009 | US7170811035

Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August 14, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the …

OppFi chief executive Todd Schwartz buys $427,680 in company stock

OppFi CEO Todd G. Schwartz purchased 60,000 shares of the company's Class A Common Stock for $427,680, following a 24% stock decline over the past week. This insider buying comes after the company reported disappointing Q2 financial results, missing analyst expectations for earnings and …

OppFi (OPFI) CEO Todd Schwartz adds 60,000 shares at $7.13 weighted price

OppFi CEO Todd G. Schwartz, a greater-than-10% owner, purchased 60,000 shares of Class A common stock on August 13, 2026, at a weighted average price of $7.128 per share through the TGS Revocable Trust. This transaction increased the trust's indirect holdings to 553,733 shares, …

How Pfizer’s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story

In early August 2026, Pfizer Inc. reported second-quarter results showing revenue of US$15,034 million and a net loss of US$248 million, alongside US$4.30 billion in non-cash intangible asset impairments and a modest increase in full-year 2026 revenue guidance to US$60.50–US$62.50 billion. A key offsetting …

Pfizer CEO Buys $1 Million of Stock

This article first appeared on GuruFocus. Pfizer Inc. (PFE, Financials) The pharmaceutical giant earned a new vote of confidence from its top executive. Albert Bourla bought about $1 million worth of company stock. Bourla purchased 38,000 shares at $26.34 apiece, which increased his ownership …

Pfizer-Aktie Prognose: Sollten Sie jetzt kaufen?

OppFi’s Guidance Cut Has Created Opportunity (NYSE:OPFI)

Pfizer (PFE) Could Be 10% Undervalued Following Raised Revenue Guidance

Pfizer, Inc. Stock 12‑Month Price Target Cut to $28.28, Implies 7% Upside

The average 12-month price target for Pfizer, Inc. (PFE) stock has been reduced from $28.47 to $28.28 by 24 analysts, with forecasts ranging from $25 to $35.75. This updated target implies a potential upside of approximately 7% from the Aug. 12 closing price. The …

5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call

5 Insightful Analyst Questions From Pfizer's Q2 Earnings Call Pfizer's second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company's performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions …

OppFi (OPFI) Stock Fair Value Falls After Analysts Reassess Guidance And Credit Risk

Oppfi CEO Todd Schwartz buys $422,988 in company stock

OppFi CEO Todd G. Schwartz recently purchased 60,000 shares of the company's Class A Common Stock for $422,988, increasing his indirect beneficial ownership through a trust. This purchase occurred as OPFI stock experienced a significant decline, yet InvestingPro analysis suggests the stock is undervalued …

OppFi (OPFI) CEO Todd Schwartz adds 60,000 shares in open-market buy

OppFi Inc. CEO Todd G. Schwartz indirectly purchased 60,000 shares of Class A common stock on August 12, 2026, at a weighted average price of $7.0498 per share through the TGS Revocable Trust. This transaction increases the trust's holdings to 493,733 shares, with Schwartz …

Insulet hires Pfizer alum Joan Campion to lead external comms

Insulet, a medical device company, has appointed Joan Campion, formerly of Pfizer, as its new VP of external communications for corporate affairs. This new role is part of a broader effort by Insulet to enhance its communications function under Chief Corporate Affairs Officer Cristal …

Listening to the Hemophilia Community: Pfizer Survey Reveals Unspoken Compromises

A Pfizer survey conducted with The Harris Poll found that many hemophilia patients and caregivers, while reporting satisfaction with current treatments, still experience significant burdens and make unspoken compromises in their daily lives. The survey, involving over 1,000 participants across four countries, highlighted challenges …

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

Pfizer is shifting its growth strategy away from COVID-19 products, focusing instead on its non-COVID portfolio through new product launches, strategic acquisitions, and pipeline development in oncology and obesity. The company's recent Q2 2026 results showed significant operational growth in non-COVID revenues, leading to …

Formation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’

Formation Bio has appointed Dr. Michael Ehlers, a former Biogen and Pfizer executive, as its new chief scientific officer and head of R&D. The company aims to leverage AI to optimize the often-overlooked "boring middle" of drug development, such as trial enrollment and site …